Learn practical strategies to reduce deviation backlogs without sacrificing investigation quality or regulatory defensibility — while building sustainable systems to prevent future accumulation.
Includes live access & recording
Deviation management remains one of the most visible indicators of quality system health within regulated pharmaceutical, biotechnology, medical device, and combination product organizations. While deviations themselves are expected in any complex operation, the accumulation of unresolved investigations often signals deeper systemic issues involving resource allocation, investigation practices, decision-making frameworks, quality culture, and operational discipline.
Many organizations struggle to balance two competing expectations. Regulatory agencies expect thorough investigations that identify true root causes and implement effective corrective actions. At the same time, business operations require timely closure of records to avoid excessive backlog growth, delayed product disposition decisions, inspection exposure, and resource consumption.
This webinar examines practical strategies for reducing deviation backlogs without sacrificing investigation quality or regulatory defensibility. Participants will learn how to establish risk-based investigation frameworks, improve decision-making consistency, focus investigative resources appropriately, and implement sustainable approaches that improve both closure performance and investigation effectiveness.
Many organizations attempt to reduce deviation backlogs through temporary initiatives, overtime efforts, or aggressive closure targets. While these approaches may produce short-term improvements, they often fail to address the underlying conditions that created the backlog in the first place.
Regulatory investigators increasingly examine not only individual deviations but also the overall health of the deviation management system. Large numbers of aging investigations, weak root cause determinations, inconsistent classifications, and poor closure discipline can all become indicators of broader quality system weaknesses.
This webinar provides practical methods for balancing investigation depth with closure efficiency while maintaining scientific rigor and regulatory credibility — with actionable approaches that can be applied immediately within regulated environments.
By the end of this session, participants will be equipped to reduce deviation backlogs while maintaining scientific rigor and regulatory defensibility.
Identify the root causes of deviation backlog accumulation and systemic drivers in regulated organizations.
Apply risk-based frameworks to determine appropriate investigation depth for each deviation type.
Establish defensible closure criteria that withstand regulatory scrutiny while supporting timely completion.
Prioritize aging investigations and allocate resources effectively using triage and workload management techniques.
Improve root cause analysis efficiency and avoid over-investigation and unnecessary scope expansion.
Develop governance models and performance metrics that support sustainable backlog reduction and prevention.
Manage recurring and repeat deviations through effective CAPA programs that prevent backlog recurrence.
Prepare deviation management systems for regulatory inspection readiness and successful oversight reviews.
Four focused areas that will transform how your organization manages deviation investigations and backlog reduction.
Learn how to match investigation depth to actual product, patient, and compliance risk — allocating resources appropriately without over or under-investigating.
Establish defensible closure criteria and decision-making standards that can withstand regulatory scrutiny while supporting timely investigation completion.
Implement sustainable governance systems that address the underlying causes of backlog growth and prevent future accumulation rather than just managing symptoms.
Prepare your deviation management system to demonstrate organizational discipline, quality culture, and effective risk management practices during regulatory inspections.
A comprehensive deep-dive across 15 critical areas of deviation management and backlog reduction in regulated manufacturing environments.
Quality, compliance, and operations professionals in pharmaceutical, biotechnology, medical device, and regulated manufacturing environments.
Vice Presidents of Quality
Quality & Compliance Directors
QA & Quality Systems Managers
Manufacturing & Operations Directors
Site Leaders & Plant Managers
Quality Engineers
Deviation Investigators
CAPA Coordinators
Validation Professionals
Regulatory Affairs Professionals
Continuous Improvement Leaders
Quality Auditors & GMP Consultants
Deviation backlogs represent far more than a collection of overdue investigations. They often reveal underlying weaknesses in quality systems, investigation processes, decision-making frameworks, resource management, and operational discipline. When left unchecked, backlog growth can increase inspection risk, delay product disposition decisions, consume valuable organizational resources, and reduce overall quality system effectiveness.
One of the greatest challenges facing quality organizations is determining how much investigation is enough. Investigations that are too superficial may fail to identify meaningful causes or implement effective corrective actions. Investigations that become excessively detailed may consume resources disproportionate to the risk presented by the event. Finding the appropriate balance between scientific rigor, operational practicality, and regulatory expectations is critical to maintaining an effective deviation management system.
This webinar explores the factors that contribute to backlog growth and examines practical strategies for improving investigation performance without compromising quality. Participants will learn how risk-based decision making can be used to allocate investigative resources appropriately, differentiate between event significance levels, and establish investigation expectations that align with actual product, patient, and compliance risks.
Special attention will be given to developing defensible closure decisions that can withstand regulatory scrutiny while supporting timely investigation completion. Participants will examine approaches for establishing investigation standards, improving cross-functional collaboration, implementing backlog reduction initiatives, measuring performance effectively, and creating governance systems that support sustainable improvement.
Charles H. Paul is the President of CHP Consulting LLC, a regulatory, training, operational excellence, and technical documentation consulting firm. Mr. Paul has more than 30 years of experience supporting pharmaceutical, biotechnology, medical device, and other regulated industries in the areas of quality systems, GMP compliance, human performance improvement, technical training, operational excellence, documentation systems, and regulatory inspection readiness.
Throughout his career, Charles has worked with organizations ranging from emerging biotechnology firms to Fortune 500 manufacturers, helping clients improve operational performance while maintaining compliance with FDA, EMA, ISO, and global regulatory expectations. His experience includes deviation management systems, investigation effectiveness, CAPA programs, quality system remediation, training system design, operational readiness, technology implementation, and workforce performance improvement.
Charles is a recognized speaker and author who has developed and delivered numerous webinars, seminars, and workshops covering quality systems, inspection readiness, technical writing, human error reduction, operational performance, project management, and regulatory compliance. His practical approach focuses on helping organizations move beyond procedural compliance to achieve sustainable operational excellence and measurable business results.
Don't miss this practical training on reducing deviation backlogs while maintaining investigation quality and regulatory defensibility.